FREDERICKSBURG, Texas, Dec. 17, 2019 /PRNewswire-PRWeb/ -- Robin Fleck, MD, board certified in internal medicine and dermatology, and medical director of Vitalité Med Spa in Fredericksburg, Texas, ...
Potential Best-in-Class TEAD Autopalmitoylation Inhibitor Supported by Promising Clinical Data SAN MATEO, Calif., July 30, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery ...
Following is a transcript of the video. Vanessa Lee: My patient today has obviously such beautiful skin, but some of her concerns are working on slight hyperpigmentation from previous breakouts. What ...
Vivace said the data from its Phase I trial (NCT04665206) showed that its lead candidate VT3989 had achieved durable anti-tumor responses in patients with advanced malignant mesothelioma and other ...
SAN MATEO, Calif., Oct. 8, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, ...
SAN MATEO, Calif., July 30, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results